Motilium Children

Quick links

Choose a section

Quick links to important sections

Advertisements

Motilium Children

Advertisements
Advertisements

Overview of Motilium Children

Property Description
Active ingredient Domperidone
Form Oral suspension
Pharmacological class Antiemetic, Prokinetic agent
General purpose Relief from nausea and vomiting
Origin Synthetic (Benzimidazole derivative)

Definition and Pharmacological Identity

Motilium Children is a medicinal preparation whose primary active ingredient is Domperidone, which belongs to the pharmacological class of prokinetic antiemetics. The substance is a synthetic compound, chemically identified as a benzimidazole derivative. The core function of this medicine is to address symptoms of sickness and manage impaired movement within the upper gastrointestinal tract.

Domperidone is scientifically classified as a selective dopamine D2 and D3 receptor antagonist. This indicates that the medicine operates by blocking specific dopamine signals in the body. It is used for the symptomatic treatment of nausea and vomiting.

Composition and Specialized Pediatric Formulation

The distinctive feature of Motilium Children is its oral suspension form, a liquid preparation with an aqueous vehicle tailored specifically for the pediatric population. The "Children" designation signals this unique liquid formulation, which is a single-ingredient product (monotherapy). This form is essential for ensuring accurate and easy oral administration for infants and young children who may have difficulty swallowing solid dosage forms.

The general principle of its action relies on peripheral dopamine receptor blockade. By acting selectively on receptors in the gut and the brain's sickness relay, Domperidone helps restore natural gastrointestinal motility and suppresses the reflex that causes vomiting, thereby aiding in swift symptomatic relief.

Advertisements

What side effects are possible with Motilium Children?

Possible Side Effects and Safety Information

Motilium Children (Domperidone) has an officially documented safety profile, categorized by frequency and the body system affected. All safety information is based on governmental regulatory sources, such as official Summaries of Product Characteristics (SmPC) and regulatory agency advisories.

Adverse Reactions by Frequency

The adverse reactions listed in official documents are classified by their expected rate of occurrence:

  • Common (1 to 10 users in 100): Dry mouth.
  • Uncommon (1 to 10 users in 1,000): Headache, drowsiness, anxiety, diarrhea, rash, and effects related to elevated prolactin levels like galactorrhea (unusual breast milk production) or breast pain/tenderness.
  • Very Rare (less than 1 user in 10,000): Serious ventricular arrhythmias (including Torsades de Pointes), sudden cardiac death, seizure, and extrapyramidal disorders (uncontrolled movements).

Serious Safety Considerations

The primary serious concern documented is the risk of QT prolongation and subsequent serious cardiac events. The medicine is strictly contraindicated (should not be used) in patients with pre-existing cardiac conditions, significant electrolyte disturbances, or underlying heart diseases, as established by regulatory documents.

Population-Specific Safety Notes

Safety statements include specific considerations for certain groups. For older adults, a higher risk of serious cardiac events has been observed. For the pediatric population, extrapyramidal symptoms are reported to be more likely to occur. The product is contraindicated in patients with moderate or severe hepatic impairment due to reduced clearance.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile details specific manifestations and mandated emergency responses in the event of an overdose.

Documented Overdose Presentations

Symptoms of overdosage documented in official labeling primarily affect the Central Nervous System (CNS) and include somnolence (drowsiness), disorientation, and confusion. Neuromuscular signs such as convulsions and extrapyramidal reactions (uncontrolled movements) are also documented overdose presentations.

Overdose symptoms, particularly the extrapyramidal reactions, are specifically noted in regulatory information as being reported mainly in infants and children.

Serious Outcomes and Emergency Actions

Overexposure carries the risk of prolongation of the QT interval on the electrocardiogram (ECG), which has been associated with serious ventricular arrhythmias, including Torsade de Pointes and Sudden Cardiac Death.

Because no specific antidote to domperidone is known, regulatory agencies mandate that immediate medical attention must be sought straight away if an overdose is suspected. In this circumstance, standard symptomatic treatment should be administered immediately. ECG monitoring must be carried out to address the potential for cardiac conduction risk. Supportive measures, such as gastric lavage or the use of activated charcoal, may be considered, and anticholinergic or anti-Parkinson medicines may be administered for the control of extrapyramidal disorders.

Advertisements

Therapeutic Uses of Motilium Children

What Motilium Children Treats: Main Uses and Benefits

Motilium Children is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms related to the digestive system.


Addressing Episodic Digestive Discomfort

The medicine is relevant for managing symptom clusters that may become intense or disruptive, such as nausea and vomiting, which may appear suddenly or fluctuate. It is used in areas where short-term symptom management is appropriate and assists with maintaining functional stability during episodes where symptoms create noticeable functional strain. The medicine is commonly used across conditions presenting with acute episodes involving these specific symptoms. The medicine contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Supportive Management for Nausea and Vomiting


Support for Symptom Management During Acute Episodes

Motilium Children may be part of symptomatic management for conditions involving recurrent or episodic manifestations that require short-term symptomatic assistance. It supports the patient during difficult episodes by easing distress and is relevant when symptoms become more noticeable, providing supportive relief that helps maintain a sense of stability. It is often applied during phases of increased distress or discomfort where symptoms linked to physical discomfort are present.

Regulatory References

  1. European Medicines Agency therapeutic use overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Motilium Children (Domperidone) use is strictly regulated based on official regulatory documents, primarily restricting the patient population to mitigate known risks and address limited efficacy data in certain groups.

Age-Related Eligibility
Allowed: Adults and adolescents aged 12 years and older who weigh 35 kg or more.
Contraindicated: Children younger than 12 years of age and adolescents weighing less than 35 kg; use in these groups is prohibited due to lack of established efficacy and unfavorable risk profile.
Conditional Use: Older adults (over 60 years) should use the medicine with caution due to a potentially higher risk of cardiac side effects.

Contraindicated Populations and Conditions

Use is contraindicated (must not be used) in patients with specific pre-existing conditions:

  • Cardiac Issues: Known prolongation of the QTc interval, underlying cardiac diseases (such as congestive heart failure), or significant electrolyte disturbances (e.g., hypokalaemia).
  • Organ Impairment: Moderate or severe hepatic impairment. For severe renal impairment, the label requires that the dosing frequency must be reduced.
  • Gastrointestinal Risk: Conditions where stimulating motility is harmful, such as gastrointestinal haemorrhage, mechanical obstruction, or perforation.
  • Other: Known hypersensitivity to domperidone or a prolactin-releasing pituitary tumour.

Pregnancy and Lactation Eligibility Status

Use during pregnancy is not recommended unless the therapeutic benefit is deemed to outweigh the potential risk. Domperidone is excreted in human milk, and a decision to use it while breastfeeding must weigh the benefit to the child against the benefit of therapy for the woman, exercising caution regarding cardiac risk factors in the infant.

Connection to the Overall Eligibility Profile

The regulatory documents formally exclude high-risk populations by defining explicit contraindications based on age, weight, and pre-existing cardiac or hepatic conditions. This ensures the medicine is reserved for the narrow patient profile where the benefit-risk ratio is considered acceptable by regulatory authorities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Motilium (domperidone) interacts with certain other medicines, which can lead to increased risks, particularly related to the heart. Co-administration is contraindicated (must not be taken together) with two main groups of medicines:

  • Medicines that prolong the QTc interval (which affects heart rhythm). These include certain antibiotics (e.g., erythromycin, moxifloxacin), antifungal agents, antimalarial agents, some heart medicines (antiarrhythmics), and certain other medicines.
  • Potent CYP3A4 inhibitors. These are medicines that slow down the breakdown of Motilium in the body, which significantly increases the domperidone concentration and the risk of QTc prolongation. Examples include some azole antifungals (e.g., oral ketoconazole, voriconazole) and certain HIV protease inhibitors.
Interaction Type Examples of Interacting Medicines/Classes
Do Not Combine (Contraindicated) QTc-prolonging medicines, Potent CYP3A4 inhibitors.
Not Recommended Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, some macrolides).
Timing Restriction Antacids or Antisecretory Agents (Do not take simultaneously; Motilium should be taken before a meal, and the interacting agent after the meal).
Antagonistic Effect Anticholinergic drugs (may counteract Motilium's digestive tract effects).

Caution is also necessary when Motilium is taken with drugs that may cause slow heart rate (bradycardia) or low potassium levels (hypokalaemia), as these conditions increase the risk of heart rhythm problems. Always inform a healthcare provider of all current medications, vitamins, and supplements.

Advertisements

Mechanism of Action

Targeted Receptor Blockade

This mechanism involves the drug acting as a selective Dopamine D2 receptor antagonist. By binding to these receptors in the Chemoreceptor Trigger Zone (CTZ), the compound engages mechanisms that regulate overactive signaling pathways associated with central emetic signaling, resulting in restricted impact of excessive mediator activity.


Mechanism to Regulate Digestive Movement

The drug modifies early molecular steps by blocking D2 receptors in the wall of the gastrointestinal tract, supporting the release of the stimulating neurotransmitter acetylcholine. This effect initiates signaling sequences that lead to increased strength and coordination of contractions, influencing the velocity of gastric contents transfer and resulting in a modified regulatory state within the targeted pathways.


Selective Action on Peripheral Systems

The medicine is relevant in systems where targeted pathway adjustment is required outside the central nervous system. Its inability to easily cross the blood-brain barrier (BBB) means it primarily modulates key pathways in peripheral and circumventricular contexts, which results in the modulation of overactive physiological responses and reduced interaction with other mechanisms within the central nervous system.

Advertisements

Dosage and Administration Information

How to Use Motilium Children (Domperidone)

These instructions outline the administration guidelines for Motilium Children (domperidone) oral suspension and are designed to facilitate proper use.

Official Administration Protocol

Guideline Element Instruction
Route Oral use only.
Dosing Up to 0.25 mg domperidone per kg body weight, up to 3 times per day. The maximum daily dose must not exceed 30 mg.
Timing Administer the dose 15 to 30 minutes before a meal, and if necessary, once before bedtime.
Duration Use should be for the shortest possible duration, generally not exceeding one week for acute symptoms.
Preparation The oral suspension bottle must be shaken well before each use.

Rules for Specific Patient Populations

Motilium Children is specifically authorized for use in adolescents aged 12 years and older and weighing 35 kg or more.

For children weighing less than 35 kg, the weight-based dosing formula (0.25 mg per kg) must be used to calculate the correct amount per intake, ensuring the maximum daily dose is not surpassed.

Missed Dose Instructions

If a dose is forgotten, skip that dose entirely. Do not take a double dose to compensate for the missed one. Resume taking the medicine at the next scheduled time as usual. Adherence to the prescribed timing and maximum daily dose is crucial for correct administration.

Advertisements

Recent Clinical Evidence

Clinical Research and Regulatory Status

The use of domperidone (Motilium) in children has been subject to extensive regulatory and clinical review, particularly regarding the balance between potential benefits and known cardiac risks. The European Medicines Agency (EMA) has evaluated available data, including recent randomized controlled trials (RCTs), focusing on its approved indication for relieving symptoms of nausea and vomiting.


Efficacy Findings in the Pediatric Population

A pivotal multicenter, placebo-controlled study examining domperidone in children under 12 years of age with acute gastroenteritis did not demonstrate a significant difference in efficacy compared to placebo in reducing episodes of vomiting and nausea. Based on these findings, regulatory bodies in Europe have restricted the product’s authorized use. Domperidone is now only authorized for the relief of nausea and vomiting symptoms in adolescents (12 years of age and older and weighing 35 kg or more).

Historically, domperidone was studied for pediatric gastroesophageal reflux (GER). Early, small-scale trials exploring its use for reflux in infants and young children were limited and did not provide robust evidence of symptomatic improvement. Current authoritative guidelines do not recommend the routine use of domperidone for GER in young children due to the lack of evidence of efficacy and the risk profile.


Cardiac Safety Considerations

The overall safety review noted an association between domperidone use and a small increased risk of serious cardiac side effects, including QT interval prolongation (an alteration of the heart's electrical activity). This risk is known to be heightened at higher doses or with prolonged treatment. Consequently, recommendations strictly limit the dosing and duration of treatment, advising use at the lowest effective dose for the shortest possible duration, generally not exceeding one week.

Key Studies & References

  1. Domperidone for gastro-oesophageal reflux in children: review and update of regulatory aspects
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Motilium Children (FAQ)

Q: Can Motilium Children be used in infants or only older children?

A: Official regulatory documentation states that this medicine is authorized for use in adults and in adolescents 12 years of age and older and weighing 35 kg or more. Official documents state that the use in younger children, especially infants, is restricted or not authorized for the relevant indication.

Q: Are there different instructions for Motilium Children based on the child's age or weight?

A: Regulatory guidelines describe that dosing and eligibility depend on certain characteristics. Guidelines confirm that dosage calculations are strictly based on the individual's body weight using a specific formula, and eligibility is also linked to certain age and weight thresholds.

Q: What is the main difference between Motilium Children and regular Motilium?

A: According to official product descriptions, both products contain the same active substance, domperidone. Motilium Children generally refers to the oral suspension (liquid) formulation. This liquid form facilitates accurate, weight-based administration typically used in the authorized pediatric population.

Q: Is Motilium Children the same as domperidone?

A: Motilium Children is a brand name. The active pharmaceutical ingredient in the medication, which provides the therapeutic effect, is domperidone.

Q: Why is Motilium Children used for stomach issues in kids?

A: Official regulatory documents state that the medicine is indicated for the relief of the symptoms of nausea and vomiting. These are the specific symptoms of stomach issues for which the drug is authorized for use in the defined patient population.

Q: How quickly should I expect to see an effect after taking the medicine?

A: Official pharmacokinetic data indicates that the active ingredient, domperidone, typically reaches its highest concentration in the blood within one to two hours after administration. This information helps define the expected speed of absorption.

Q: Does Motilium Children cause drowsiness or make children sleepy?

A: According to official product information, somnolence, which means drowsiness or sleepiness, is listed as an uncommon side effect. Uncommon means it may affect up to 1 in 100 people who use the medicine.

Q: Are there any common foods or drinks that might interact with this medicine?

A: Official instructions focus on the timing of administration relative to food. Regulatory documents state that the medicine should be taken 15 to 30 minutes before a meal because taking it after eating may reduce how much of the drug the body absorbs.

Q: What kind of stomach issues is this medicine officially used for?

A: The medicine is officially indicated for the relief of symptoms of nausea and vomiting. This is the specific authorized use described in regulatory documents for the defined patient populations.

Q: If a dose is missed, what is the generally described action to take?

A: The official Patient Information Leaflet generally describes that if a dose is missed, the recommended action is to skip the missed dose. Regulatory instructions indicate that patients should not take a double dose to compensate for a missed one.

Q: Why do official sources mention heart-related concerns with this type of medicine?

A: Regulatory documents highlight a small increased risk of serious adverse cardiac reactions (heart-related issues) associated with domperidone. This includes an association with QT interval prolongation. This potential risk is why official usage guidelines impose restrictions on dose and duration.

Q: What is the function of the ingredient 'domperidone' in the body?

A: Domperidone is officially classified as a dopamine antagonist. This means it works by blocking chemical signals from dopamine receptors. This action helps to increase motility (movement) through the upper digestive tract.

Q: Do children usually experience a metallic taste or dry mouth after taking it?

A: Official product documentation reports dry mouth as a common side effect, meaning it may affect up to 1 in 10 people. The official documentation does not list metallic taste among the most frequently reported side effects.

Q: Can this medicine cause changes in a child's mood or behavior?

A: Official product documentation does list certain effects on the nervous system and psychiatric health as uncommon side effects. These can include feelings of anxiety, restlessness, or nervousness.

Q: Is the liquid form more common than tablets for children?

A: The formulation most often authorized and labelled for the pediatric population is the oral suspension, which is the liquid form. This formulation is used because it allows for the precise, weight-based measurement required for the treatment of children and adolescents.

Q: Are there any known allergies that would prevent a child from taking this?

A: Official documents state that this medicine is contraindicated (must not be used) if a child has a known hypersensitivity or allergy to the active ingredient, domperidone, or to any of the other ingredients in the product formulation.

Q: What are the most frequent side effects reported in clinical trials?

A: Official documentation lists the frequency of reported side effects, noting dry mouth as a common event. Less common, or uncommon, effects reported include anxiety, diarrhea, and restlessness.

Q: Can a child still attend school or play sports while taking Motilium Children?

A: Due to the possibility of uncommon side effects like dizziness or somnolence (drowsiness), official guidance indicates that patients should be aware of potential impairment to mental alertness. This applies to any activity requiring concentration.

Q: What are the official restrictions on who should NOT take this medicine?

A: Official documents state that the medicine is contraindicated (should not be used) in patients with conditions like moderate or severe liver impairment, certain pre-existing heart conditions, or when specific types of interacting medicines are being taken.

Q: What happens if the child takes Motilium Children and an antibiotic at the same time?

A: Regulatory documents state that domperidone is contraindicated with specific types of medicines, including certain antibiotics. This restriction is due to the potential that those combinations could increase the risk of serious heart side effects.

Q: Is there any evidence about Motilium Children's use in children with kidney problems?

A: Regulatory guidance indicates that for patients with severe renal impairment (significant kidney problems), the dosing frequency may need to be reduced. These patients are typically subject to regular review during treatment.

Q: How does Motilium Children affect how food moves through the digestive system?

A: The medicine is described in official documents as a prokinetic agent. This means it acts to increase motility (movement) through the upper portion of the digestive system, such as the stomach and the beginning of the small intestine.

Q: What is meant by the term 'contraindication' regarding this drug?

A: A contraindication is a term used in regulatory documents to denote a condition, disease, or other factor that makes the use of this drug strictly prohibited. Using the medicine when a contraindication is present is considered unsafe or potentially harmful.

Q: Are there different dose strengths available, and what do they mean?

A: The product is typically formulated at a specific strength, often expressed as mg of domperidone per mL of liquid (e.g., 1 mg/ mL). This number indicates the concentration of the active ingredient present in the oral suspension.

Q: Does the medicine come with a special measuring device?

A: Official instructions emphasize accurate liquid measurement, particularly for weight-based dosing in children. Therefore, the oral suspension product is generally supplied with a dedicated, calibrated measuring device, such as a syringe or cup, for precise administration.

Q: What does the term 'pharmacovigilance' mean in the context of this drug's safety?

A: Pharmacovigilance is the ongoing regulatory process of monitoring the safety of a medicine once it is on the market. Official documents include sections on reporting suspected adverse reactions (side effects) from patients and healthcare providers, which is a key part of this monitoring.

Q: Are there certain existing medical conditions that prevent its use?

A: Official regulatory guidance specifies several existing medical conditions that prevent the use of this medicine. These include pre-existing issues such as moderate or severe liver impairment, certain heart conditions, and internal problems like a bleeding or blocked intestine.

Q: What is the general advice if a child takes too much of this medicine?

A: Regulatory documents describe possible symptoms in the event of an overdose. These symptoms can include agitation, drowsiness, changes in consciousness, and extrapyramidal reactions (uncontrolled movements). Immediate medical attention is generally required in such circumstances.

Q: What if the child is taking vitamins or herbal supplements? Can they still take Motilium Children?

A: While official contraindications usually focus on prescription and over-the-counter drugs, it is important that the use of all supplements or herbal products be disclosed, as the list of known interactions may not be exhaustive.

Q: Why is there a focus on the lowest effective dose in the official documents?

A: Official regulatory documents strictly advise using the lowest effective dose for the shortest possible duration. This focus is associated with the need to manage the small, increased risk of serious adverse cardiac effects.

Q: Do any official documents describe its use for gastroesophageal reflux (GER) in infants?

A: Official regulatory indications confirm that domperidone use is not recommended for common chronic conditions, such as routine infant gastroesophageal reflux (GER). This restriction is stated clearly in official indications due to safety concerns identified during the regulatory review process.

Q: What are the officially described rare, but serious, side effects?

A: Regulatory documents describe certain rare or very rare side effects that can be serious. These include severe allergic reactions (such as swelling of the face, tongue, or throat) and, as previously mentioned, certain heart rhythm disorders.

Q: Is Motilium Children metabolized by the liver?

A: Yes, official pharmacokinetic descriptions indicate that the drug is extensively processed, or metabolized, by specific enzymes in the liver. This metabolism is a key reason why liver impairment is listed as a contraindication for the medicine's use.

Q: What does official guidance say about driving or operating machinery for older children taking this?

A: Official guidance on activities like driving or operating machinery applies generally to the potential side effects of the drug. Since the medicine may cause dizziness or somnolence (drowsiness), caution is advised for any activity that requires full mental alertness and concentration.

Q: Does the patient information leaflet provide specific instructions on storage?

A: Yes, the patient information leaflet contains specific instructions for proper storage. These instructions commonly advise that the medicine be kept out of the sight and reach of children and specify conditions like maintaining a temperature below a certain limit.

Q: How can parents report suspected side effects to the authorities?

A: Official product documentation includes the necessary details and procedures for patients and caregivers to report suspected adverse reactions (side effects). This reporting is directed to the relevant national regulatory authority overseeing drug safety.

Q: What is the role of the EMA or FDA regarding the use of domperidone in children?

A: Regulatory bodies like the EMA or FDA are responsible for continuously reviewing the benefit-risk profile of the drug. Their function includes issuing and updating restrictions and warnings to help optimize the safety profile of the medicine.

Q: Is there a generic version of Motilium Children available?

A: The active ingredient in this medicine is domperidone, which is manufactured and distributed by companies other than the original developer. These products are often available on the market and may be referred to as generic equivalents.

Q: Why is there a warning about using this medicine with other QT-prolonging drugs?

A: Official regulatory warnings are mandatory because taking domperidone with other medicines known to prolong the QT interval on an electrocardiogram increases the risk of serious cardiac adverse effects. This combination is generally contraindicated as a regulatory measure to minimize cardiac risk.

Q: Do clinical trial results for Motilium Children apply to all children?

A: Clinical trial results and the authorized use of the medicine are explicitly restricted to specific patient populations. Official documents clarify that use is currently restricted to adolescents 12 years of age and older and weighing 35 kg or more for the authorized indications.

Q: Is it true that the medicine works by blocking a chemical in the brain and gut?

A: Yes, official documents describe domperidone as working by blocking dopamine receptors. These receptors are found both in the area of the brain that controls vomiting and within the wall of the gut, contributing to its effect on nausea and motility.

Q: What are the signs of an allergic reaction described in the official documents?

A: Signs of a serious allergic reaction described in official sources include swelling of the hands, feet, face, or throat, known as angioedema. Other very serious signs of an anaphylactic reaction include difficulty breathing or severe dizziness.

Q: Is there any information on how Motilium Children affects growth or development?

A: Official regulatory documents contain safety information primarily focused on the short-term, authorized use in the defined patient population. They do not contain specific claims or definitive statements regarding any potential long-term impacts on a child's overall growth or development.

Advertisements

How should Motilium Children be stored and disposed of?

Motilium oral suspension must be stored according to specific regulatory requirements to maintain its stability and ensure safety.

Storage Requirements

The product must be stored at a controlled room temperature, typically not exceeding 25 C or 30 C, as specified on the label. Regulatory guidance explicitly states to not refrigerate or freeze the suspension.

It is mandatory to keep the medicine out of the sight and reach of children and to store it in the original container with the child-resistant cap tightly closed after each use.

Disposal Instructions

Disposal of any unused or expired Motilium suspension must be carried out in accordance with local regulatory requirements. The medicine must not be thrown away via wastewater or household waste to prevent environmental contamination. Patients should consult a pharmacist or local authority for approved disposal methods, such as drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Motilium Children found in:

A-Z Index: